What is William Blair's Forecast for VERV Q1 Earnings?

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Research analysts at William Blair issued their Q1 2026 EPS estimates for Verve Therapeutics in a report issued on Thursday, February 27th. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.77) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share. William Blair also issued estimates for Verve Therapeutics' Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.75) EPS and Q4 2026 earnings at ($0.77) EPS.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.14. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The company had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million.

A number of other research analysts have also recently commented on VERV. HC Wainwright raised their target price on Verve Therapeutics from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Canaccord Genuity Group raised their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reduced their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Verve Therapeutics has an average rating of "Buy" and an average price target of $25.50.

Remove Ads

Verve Therapeutics Price Performance

VERV stock traded down $0.52 during trading on Monday, reaching $6.03. The company had a trading volume of 491,732 shares, compared to its average volume of 1,528,540. The business has a 50 day moving average of $6.93 and a 200 day moving average of $6.05. The company has a market cap of $510.52 million, a P/E ratio of -2.45 and a beta of 1.74. Verve Therapeutics has a 52 week low of $4.30 and a 52 week high of $16.03.

Institutional Investors Weigh In On Verve Therapeutics

A number of institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock worth $34,000 after purchasing an additional 3,964 shares in the last quarter. IFP Advisors Inc lifted its stake in shares of Verve Therapeutics by 823,700.0% in the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock worth $47,000 after buying an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Verve Therapeutics during the fourth quarter valued at approximately $50,000. Creative Planning bought a new stake in shares of Verve Therapeutics during the third quarter valued at approximately $50,000. Finally, Erste Asset Management GmbH purchased a new position in Verve Therapeutics in the 3rd quarter worth approximately $56,000. 97.11% of the stock is owned by hedge funds and other institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.